A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)-- #ASCO26--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for solid tumors, today announced the presentation of safety and efficacy data from the ongoing EVEREST-2 clinical study (NCT06051695). The findings, which are being presented in poster presentations during the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 29 – June 2, 2026, in Chicago, include upd